TRIAL OF LIVE (PRIVATE) RECOMBINANT CANARYPOX ALVA-HIV VCP205 IN HIV

研究的具体目的是：(1)评估安全和 描述接种的两种候选HIV-1疫苗的反应性 同时：ALVAC vCP205和SF-2 RGP 120；(2)体液评估 以及这种疫苗组合的细胞免疫原性；(3)比较 两种候选抗体组合的反应性和免疫原性 针对感染HIV-1风险较低和风险较高的个人接种疫苗； (4)评估进行预防性HIV-1疫苗效力的可行性 通过现有的HIVNET结构在高危人群中进行试验， 包括招募和留住不同的高风险人群的能力 个人参与预防性HIV-1疫苗试验；和(5)评估 预防性研究参与者潜在的行为和社会风险 HIV-1疫苗试验。

The specific aims of the study are to: (1) evaluate the safety and describe the reactogenicity of two candidate HIV-1 vaccines administered simultaneously: ALVAC vCP205 and SF-2 rgp 120; (2) evaluate the humoral and cellular immunogenicity of this combination of vaccines; (3) compare reactogenicity and immunogenicity of this combination of two candidate vaccines in individuals at lower risk and higher risk of HIV-1 infection; (4) assess the feasibility of conducting preventive HIV-1 vaccine efficacy trials in high risk populations through the existing HIVNET structure, including the ability to recruit and retain a diverse cohort of high risk individuals into preventive HIV-1 vaccine trials; and (5) evaluate potential behavioral and social risks to study participants in preventive HIV-1 vaccine trials.